ArticleMedical & biological engineering & computing2026
Machine learning-based stratification of chagas heart failure severity using ECG power spectral biomarkers.
Article in Medical & biological engineering & computing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study presents a machine learning methodology to automatically classify heart failure severity in Chagas disease (CD) patients using non-invasive 24-hour ECG-Holter signals.
methodsFollowing American Heart Association (AHA) guidelines, the cohort was stratified into three Left Ventricular Ejection Fraction (LVEF)-based severity groups: Normal (LVEF ≥ 0.50, n=197), Moderate (0.40 ≤ LVEF < 0.50, n=106), and Severe (LVEF < 0.40, n=77), totaling N=380 patients. From short 10-second ECG segments, we extracted eleven spectral features derived from the power spectral density (PSD). Class imbalance was addressed through oversampling applied to the training folds. All classifiers were evaluated over 50 random stratified train-test splits (80/20) across three pairwise tasks (Normal vs. Moderate, Normal vs. Severe, Moderate vs. Severe).
resultsAnalysis revealed a consistent leftward shift in PSD, with increased low-frequency power in more severe cases, consistent with morphological ECG changes including P-wave attenuation, QRS alterations, and ST-segment shifts. Using this spectral biomarker, the best models achieved mean AUC/PR-AUC values of 0.79/0.76 for Normal vs. Severe and 0.83/0.85 for Moderate vs. Severe across 50 random states. The Normal vs. Moderate task showed moderate separability (AUC = 0.75, PR-AUC = 0.72).
conclusionThese findings highlight the potential of power spectral ECG analysis as a low-cost, fully automated tool for risk stratification in CD. The methodology shows promise for improving triage and clinical decision-making in resource-limited settings where CD remains highly prevalent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.